Research has shown that patients of color prefer seeing doctors of their own race — and some studies have shown health outcomes are better for Black patients seeing Black doctors.
The World Health Organization has issued warnings about falsified semaglutides used in diabetes and weight-loss drugs, following the detection of altered batches of products in Brazil, the UK, and the U.S.
Nestle introduces Vital Pursuit, a new food brand tailored for people taking weight-loss drugs like Wegovy, focusing on high-protein, nutrient-dense meals while navigating regulatory concerns and competition in the growing market targeting GLP-1 medication users.
Cyberattack on Ascension hospitals across the U.S. compromises patient care, leading to medication errors, delayed lab results, and patient safety risks, as health workers struggle without access to critical electronic systems.
KFF Health News
Daily News
Stay up to date with the latest clinical headlines.
Intensive behavioral counseling, recommended for U.S. children with obesity, remains largely inaccessible due to insurance and availability issues, leaving many families without critical support.
Merck is pursuing next-generation cardiometabolic drug opportunities, focusing on small-molecule oral treatments with potential benefits beyond weight loss, including improvements in cardiovascular and diabetes outcomes.
Emerging evidence that weight-loss drugs like Wegovy and Zepbound can reduce heart disease risk and treat sleep apnea may attract more male users, despite existing social and cultural barriers to seeking medical treatment for weight management.
Kroger Health revamps its weight management program to include GLP-1 drugs like Wegovy and Zepbound, offering in-person and telehealth visits starting at $99.